Physician profile
Lara Decastro
NPI 1518665553
$2,212.07
in general payments reported to CMS, 2019-2025
12 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $504 · 2024: $695 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,063.28 | 2023-2025 | |
| Siemens Medical Solutions USA, INC. | $167.12 | 2024 | Mammomat Inspiration, Mammomat Revelation |
| Lundbeck LLC | $161.58 | 2023-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $149.87 | 2025 | Rexulti, Jynarque |
| Medtronic, INC. | $145.22 | 2024 | Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $124.77 | 2023 | Ultomiris |
| Ucb, INC. | $123.82 | 2023 | Nayzilam |
| Argenx US, INC. | $114.23 | 2024 | Vyvgart Hytrulo |
| Csl Behring | $90.12 | 2025 | Hizentra |
| Biogen, INC. | $36.76 | 2025 | Vumerity |
| Impel Pharmaceuticals LLC | $21.69 | 2025 | Trudhesa |
| Sk Life Science, INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Decastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.